Cargando…

SMC decisions: December 2020

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	News Item
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728461/ https://www.ncbi.nlm.nih.gov/pubmed/33324031 http://dx.doi.org/10.1007/s40274-020-7367-3

Ejemplares similares

SMC November 2020 decisions
Publicado: (2020)

Scottish Medicines Consortium September 2020 decisions
Publicado: (2020)

EMA's CHMP meeting highlights from September 2020
Publicado: (2020)

ISMP releases Top 10 list of medication errors and hazards in 2020
Publicado: (2021)

In the literature: December 2020
por: Gambardella, V., et al.
Publicado: (2021)

News and Views December 2020
Publicado: (2020)

HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)

Remdesivir-related acute kidney injury in patients with COVID-19
Publicado: (2020)

UK's MHRA publishes guidance for valproate PPP during pandemic
Publicado: (2020)

COVID-19 pregnancy prevention guidance on teratogenic drugs
Publicado: (2020)

TGA advises of potential taste disturbance with Andrographis paniculata
Publicado: (2020)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

New potential interaction with emergency COVID-19 medicine remdesivir
Publicado: (2020)

Women disadvantaged by employment-based health financing
Publicado: (2020)

Codeine-containing medicines to be reclassified in NZ
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Concerns raised with MHRA of anticoagulant use during pandemic
Publicado: (2020)

Phase III trial of Covid-19 treatment paused for safety concerns
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Non-serious case reports
Publicado: (2020)

EMA releases highlights from the CHMP's July meeting
Publicado: (2020)

Non-serious case reports
Publicado: (2020)

ISMP issues safety warnings for drug shortage replacement products
Publicado: (2020)

Risks of chloroquine or hydroxychloroquine use for COVID-19
Publicado: (2020)

Medsafe: potentially fatal adverse effects with Miracle Mineral Solution
Publicado: (2020)

Other adverse reaction research
Publicado: (2020)

Antimalarial use in COVID-19 patients requires close monitoring
Publicado: (2020)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Certain Emerade adrenaline auto-injector pens being recalled in UK
Publicado: (2020)

Hydroxychloroquine: risk of QT prolongation and drug interactions
Publicado: (2020)

Health Canada approves first drug for treatment of COVID-19
Publicado: (2020)

NICE consulting on methods used for health technology evaluation
Publicado: (2020)

EMA guidance on risk management plans for COVID-19 vaccines reviewed
Publicado: (2020)

ICER's second update to pricing models of remdesivir for COVID-19
Publicado: (2020)

EMA's safety monitoring plan for COVID-19 vaccines
Publicado: (2020)

Policy options discussed for pricing novel COVID-19 vaccines/treatment
Publicado: (2020)

ICER update to pricing models of remdesivir for COVID-19
Publicado: (2020)

ICER's timelines for assessments extended due to COVID-19
Publicado: (2020)

Labelling or packaging variation implementation time extended
Publicado: (2020)

Serious cardiac AEs with hydroxychloroquine during COVID-19 pandemic
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qf76m896g6jnm3c901e5sf7rah